Mihaela Cristea is an Oncology physician affiliated with Regeneron. OpenAlex indexes 226 publications with 5,218 citations (h-index 33); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S
Orange, CA 928683201
Telephone
714-456-8888Provider last certified this registry record 25 Nov 2025.
Clinical trials
- p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
Sponsor: City of Hope Medical Center
- Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
Sponsor: City of Hope Medical Center
- Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Poly(ADP-Ribose) Polymerase Inhibitor100%Lynparza100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer
Journal for ImmunoTherapy of Cancer
2024 - Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Nature Communications
2023 - NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Kimberly
Regeneron
Robert Vitti, MD
Regeneron
Thomas Uldrick, MD
Regeneron
Andrew Fontenot, MD
Regeneron
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”